RT Journal Article SR Electronic T1 CFTR-mediated monocyte-macrophage dysfunction revealed by cystic fibrosis proband- parent comparisons JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.30.21259182 DO 10.1101/2021.06.30.21259182 A1 Zhang, Xi A1 Moore, Camille A1 Harmacek, Laura A1 Domenico, Joanne A1 Rangaraj, Vittobai A1 Ideozu, Justin E. A1 Knapp, Jennifer R. A1 Woods, Kate A. A1 Jump, Stephanie A1 Jia, Shuang A1 Prokop, Jeremy W. A1 Bowler, Russel A1 Hessner, Martin J. A1 Gelfand, Erwin W. A1 Levy, Hara YR 2021 UL http://medrxiv.org/content/early/2021/07/02/2021.06.30.21259182.abstract AB Cystic fibrosis (CF) is an inherited disorder caused by biallelic mutations of the cystic fibrosis transmembrane conductance regulator gene (CFTR). Converging lines of evidence suggest that CF carriers with only one defective CFTR copy are at increased risk for CF-related conditions and pulmonary infections, but the molecular mechanisms underpinning this effect remain unknown. Here, we performed transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) of CF child-parent trios (proband, father, and mother) and healthy control PBMCs or THP-1 cells incubated with the plasma of these subjects. Transcriptomic analyses revealed suppression of cytokine-enriched immune-related genes (IL-1β, CXCL8, CREM) implicating lipopolysaccharide tolerance in innate immune cells (monocytes) of CF probands and their parents and in the control innate immune cells incubated with proband or parent plasma. These data suggest that not only a homozygous but also a heterozygous CFTR mutation can modulate the immune/inflammatory system. This conclusion is further supported by the findings of lower numbers of circulating monocytes in CF probands and their parents compared to healthy controls, the abundance of mononuclear phagocyte subsets (macrophages, monocytes, and activated dendritic cells) which correlated with Pseudomonas aeruginosa infection, lung disease severity, and CF progression in the probands. This study provides insight into demonstrated CFTR-related innate immune dysfunction in individuals with CF and carriers of a CFTR mutation that may serve as a target for personalized therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the National Heart, Lung, and Blood Institute grant 1DP2OD007031-01 (H.L.), Stanley Manne Children's Research Institute grant 939001 (H.L.), Ann and Robert H. Lurie Children's Hospital (H.L.) and National Jewish Health(H.L.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Boards (CHW 07/72, GC 390, CTSI 847, CHW 01-15 Children Hospital of Wisconsin, 2015-400 Ann & Robert H. Lurie Children Hospital of Chicago, NJH HS-3648 National Jewish Health). The Biomedical Research Alliance of New York (BRANY) IRB is the current IRB providing oversight for this study at National Jewish Health.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.